Immunoliposomes in vivo.
Attachment of antibodies to the surface of liposomes was performed to confer specificity for a certain cell or organ expressing the targeted antigenic determinant. These so-called immunoliposomes are expected to be applied as targeted drug carriers. In this article, the literature concerning in vivo studies of the targeting of immunoliposomes to various sites in the body is reviewed. The anatomical, physiological, and pathological constraints and current progress are described. Moreover, perspectives on the therapeutic feasibility of this drug targeting system are discussed.
Vingerhoeds
M H
MH
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands.
Storm
G
G
Crommelin
D J
DJ
D000666:Amphotericin B / Q000008:administration & dosage; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001682:Biological Availability; D002177:Candidiasis / Q000188:drug therapy; D002738:Chloroquine / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004337:Drug Carriers; D004339:Drug Compounding; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D007275:Injections, Intravenous; D008081:Liposomes / Q000008:administration & dosage / Q000493:pharmacokinetics; D008168:Lung / Q000378:metabolism; D008198:Lymph Nodes / Q000378:metabolism; D008288:Malaria / Q000188:drug therapy; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy; D010529:Peritoneal Cavity; D010962:Plasmodium berghei; D051381:Rats; D014018:Tissue Distribution
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004337:Drug Carriers; D018796:Immunoconjugates; D008081:Liposomes; D000666:Amphotericin B; D002738:Chloroquine